United Capital Financial Advisors LLC bought a new position in shares of Insulet Corporation (NASDAQ:PODD – Free Report) in the second quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 8,086 shares of the medical instruments supplier’s stock, valued at approximately $1,231,000.
A number of other institutional investors have also bought and sold shares of the company. Formula Growth Ltd. acquired a new position in shares of Insulet in the 2nd quarter valued at about $1,826,000. Jefferies Financial Group Inc. acquired a new stake in Insulet during the second quarter worth approximately $7,371,000. Public Employees Retirement System of Ohio bought a new stake in Insulet in the second quarter worth approximately $3,023,000. Capstone Investment Advisors LLC bought a new stake in Insulet in the second quarter worth approximately $599,000. Finally, Proficio Capital Partners LLC acquired a new position in Insulet in the second quarter valued at approximately $535,000.
Insulet Stock Up 1.2%
Shares of NASDAQ PODD opened at $145.13 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 2.48 and a quick ratio of 1.83. The company has a 50-day moving average price of $154.46 and a 200-day moving average price of $181.15. The stock has a market capitalization of $10.06 billion, a P/E ratio of 27.13, a P/E/G ratio of 1.14 and a beta of 1.10. Insulet Corporation has a 1 year low of $126.40 and a 1 year high of $354.88.
Wall Street Analysts Forecast Growth
Several brokerages have recently commented on PODD. Citigroup raised their price objective on shares of Insulet from $165.00 to $172.00 and gave the stock a “neutral” rating in a research report on Wednesday, July 8th. JPMorgan Chase & Co. restated a “neutral” rating and issued a $152.00 price target (down from $275.00) on shares of Insulet in a report on Thursday, August 6th. TD Cowen decreased their price target on shares of Insulet from $294.00 to $144.00 and set a “hold” rating for the company in a research note on Thursday, August 6th. Sanford C. Bernstein dropped their price objective on shares of Insulet from $200.00 to $175.00 and set an “outperform” rating on the stock in a report on Thursday, August 6th. Finally, Stifel Nicolaus cut their price objective on shares of Insulet from $225.00 to $180.00 and set a “buy” rating on the stock in a research report on Thursday, August 6th. Fourteen equities research analysts have rated the stock with a Buy rating, eleven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $195.40.
Get Our Latest Stock Analysis on PODD
Insider Activity
In other Insulet news, Director Timothy C. Stonesifer bought 2,790 shares of the stock in a transaction dated Wednesday, June 3rd. The shares were bought at an average cost of $143.51 per share, for a total transaction of $400,392.90. Following the purchase, the director directly owned 9,041 shares of the company’s stock, valued at approximately $1,297,473.91. This trade represents a 44.63% increase in their position. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. 0.36% of the stock is currently owned by corporate insiders.
Key Insulet News
Here are the key news stories impacting Insulet this week:
- Positive Sentiment: Insulet’s latest reported quarter showed strong fundamentals: revenue rose 23.5% year over year to $801.7 million, while adjusted earnings of $1.66 per share exceeded the $1.47 analyst consensus. The company has also issued fiscal 2026 earnings guidance, with analysts projecting approximately $6.51 per share. Insulet financial and trading information
- Neutral Sentiment: Multiple law firms—including Rosen, Bragar Eagel & Squire, Bronstein Gewirtz & Grossman, Faruqi & Faruqi, and Robbins Geller—reminded investors that August 31, 2026 is the deadline to seek lead-plaintiff status in the securities class action. The notices generally cover purchases made between February 21, 2025 and May 26, 2026, although one complaint cites a later starting date of May 21, 2025. Rosen Insulet deadline notice
- Negative Sentiment: The litigation creates an overhang because investors allege Insulet and certain officers violated federal securities laws and seek damages. The notices reference two Omnipod medical-device corrections and a decline of more than $90 per share from pre-disclosure levels, potentially increasing concerns about product quality, disclosure practices, legal costs, and reputational risk. The allegations have not been proven. Insulet investor litigation alert
About Insulet
Insulet Corporation is a medical device company headquartered in Acton, Massachusetts, that develops, manufactures and sells insulin-delivery systems for people with diabetes. The company’s core business is the design and commercialization of its Omnipod family of tubeless, wearable insulin pumps and the consumable Pods that deliver insulin. Insulet’s products aim to simplify insulin delivery for people with type 1 diabetes and insulin-requiring type 2 diabetes by offering an alternative to traditional insulin pens and tethered pump systems.
The company’s product portfolio includes the Omnipod System line—disposable, waterproof Pods that adhere to the skin and deliver insulin—and the associated controllers and mobile applications used to program and monitor insulin delivery.
Featured Articles
- Five stocks we like better than Insulet
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Insulet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Insulet and related companies with MarketBeat.com's FREE daily email newsletter.
